FDA Grants Approval for High Dose SPINRAZA to Benefit SMA Patients

FDA Approves High Dose SPINRAZA Regimen for SMA

On March 30, 2026, Biogen announced that the FDA has approved the High Dose regimen of SPINRAZA™ (nusinersen), a significant milestone for the spinal muscular atrophy (SMA) community. According to Cure SMA, the leading nonprofit organization supporting individuals affected by SMA, this new treatment option is expected to improve care and outcomes for patients.

What is SPINRAZA?

SPINRAZA is an innovative antisense oligonucleotide therapy aimed at increasing the levels of survival motor neuron (SMN) protein. This protein is crucial for the function of motor neurons, and insufficient levels can lead to the debilitating effects commonly seen in SMA patients. The newly approved High Dose regimen is designed to further enhance the production of SMN protein, potentially leading to better therapeutic outcomes.

The Importance of This Approval

Kenneth Hobby, President of Cure SMA, emphasized the significance of the FDA's decision, stating that it represents a major advancement for the SMA community. “This new regimen offers hope for even stronger outcomes and more individualized care for people living with SMA,” he noted, emphasizing the need for tailored treatment plans that meet the unique needs of those affected by this condition.

The approval is a culmination of decades of research, clinical trials, and contributions from families, healthcare professionals, and researchers who have collectively driven progress in SMA treatment. The commitment of the SMA community has been instrumental in achieving this government approval.

Community Webinar for Education and Access

In response to this groundbreaking news, Cure SMA plans to host a community webinar on April 30, 2026. The webinar will be dedicated to educating individuals and families about the High Dose regimen of SPINRAZA, discussing its implications, and outlining steps to ensure broad access and patient support. Jackie Glascock, Chief Scientific Officer at Cure SMA, expressed the organization's commitment to helping families navigate this new treatment option, ensuring they fully understand its benefits and how to access it.

Acknowledgments to Contributors

Cure SMA also expressed deep gratitude to the individuals living with SMA and all those who contributed to this milestone, including donors, advocates, and researchers. Over the past three decades, Cure SMA has invested more than $92 million into research for SMA, which has significantly contributed to the development of therapies like the High Dose regimen of SPINRAZA. Participation in clinical trials has proven essential for generating the data required to support the approval and advancement of treatment options for this community.

Looking Forward

As the SMA community embraces this recent breakthrough, Cure SMA acknowledges Biogen's ongoing commitment to expanding therapeutic avenues for SMA treatment. They also appreciate the FDA for addressing the unmet needs of the SMA population and facilitating the development of innovative treatments. The organization encourages healthcare professionals to reach out for additional information regarding this approval and the associated support resources that are now available.

To learn more about the upcoming webinar and additional resources for SMA patients and families, visit CureSMA.org. This approval marks a hopeful new chapter for those affected by SMA, ushering in enhanced treatment possibilities and individualized care pathways.